Sugi Predict

Sugi Predict / Compounds / SCHEMBL4391847

SCHEMBL4391847

SCHEMBL4391847

Cc1cccc(-c2ncccn2)c1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 5/20 0.57
▸ CLK4 Q9HAZ1 2/20 0.57
▸ DYRK1A Q13627 1/20 0.57
▸ GRM5 P41594 1/20 0.50
▸ ACHE P22303 2/20 0.49
▸ BCHE P06276 1/20 0.49
▸ IDO1 P14902 1/20 0.48
▸ METAP2 P50579 1/20 0.48
▸ NISCH Q9Y2I1 1/20 0.47
▸ NPC1 O15118 3/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ HPGD P15428 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ CYP2A6 P11509 1/20 0.45
▸ MAPK14 Q16539 1/20 0.45
▸ TP53 P04637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17051415 0.86 RAB9A (0.58) RAB9ACLK4DYRK1AGRM5ACHE
SCHEMBL16727393 0.84 RAB9A (0.55) RAB9AACHEBCHEIDO1METAP2
SCHEMBL28811414 0.84 CNR2 (0.52) RAB9ACLK4DYRK1AGRM5ACHE
SCHEMBL29786730 0.84 CNR2 (0.52) RAB9ACLK4DYRK1AGRM5ACHE
SCHEMBL14961829 0.83 CLK4 (0.61) RAB9ACLK4DYRK1ANPC1SMN1; SMN2
SCHEMBL17018028 0.83 RAB9A (0.53) RAB9AACHEIDO1METAP2NPC1
SCHEMBL14951065 0.82 RAB9A (0.53) RAB9ACLK4GRM5NPC1SMN1; SMN2
SCHEMBL3766697 0.81 RAB9A (0.73) RAB9AACHEIDO1METAP2NPC1
SCHEMBL29786701 0.79 RAB9A (0.50) RAB9AACHEIDO1METAP2NPC1
SCHEMBL16727394 0.79 RAB9A (0.50) RAB9AGRM5ACHEIDO1METAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117898038-A Light receiving device, light receiving/emitting device, and electronic apparatus 株式会社半导体能源研究所 2024-04-16 — — CN disclosed
CN-117858542-A Display device manufacturing method and display device 株式会社半导体能源研究所 2024-04-09 — — CN disclosed
CN-111279505-B Light emitting element, display device, electronic device, and lighting device 株式会社半导体能源研究所 2024-04-09 — — CN disclosed
CN-108598107-B Display device, display module and electronic equipment 株式会社半导体能源研究所 2024-04-02 — — CN disclosed
CN-117796175-A Photoelectric conversion device and display device 株式会社半导体能源研究所 2024-03-29 — — CN disclosed
CN-117715451-A Light-emitting element, light-emitting device, electronic apparatus, and lighting device 株式会社半导体能源研究所 2024-03-15 — — CN disclosed
CN-117694032-A Light receiving device, light receiving/emitting device, and electronic apparatus 株式会社半导体能源研究所 2024-03-12 — — CN disclosed
CN-117651444-A Display device, display module and electronic equipment 株式会社半导体能源研究所 2024-03-05 — — CN disclosed
CN-112204033-B Organic compound, light-emitting element, light-emitting device, electronic device, and lighting device 株式会社半导体能源研究所 2024-02-06 — — CN disclosed
CN-117440723-A Display device, display module and electronic equipment 株式会社半导体能源研究所 2024-01-23 — — CN disclosed
US-7807672-B2 Compounds that are ERK inhibitors SCHERING CORPORATION (US) 2010-10-05 — — US disclosed
WO-2010025235-A1 SELECTIVE LIGANDS FOR THE DOPAMINE 3 (D3) RECEPTOR AND METHODS OF USING THE SAME REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2010-03-04 — — WO disclosed
US-20090306038-A1 2-Aminopyrimidine derivatives as modulators of the histamine H4 receptor activity PALAU PHARMA, S.A. (ES) 2009-12-10 — — US disclosed
US-7312201-B2 Tetracyclic bicyclolides ENANTA PHARMACEUTICALS, INC. (US) 2007-12-25 — — US disclosed
US-20070232610-A1 Novel compounds that are ERK inhibitors SCHERING CORPORATION 2007-10-04 — — US disclosed
US-7189704-B2 6-11 bicyclic ketolide derivatives ENANTA PHARMACEUTICALS, INC. (US) 2007-03-13 — — US disclosed
US-6613747-B2 Erythromycins to treat community-acquired pneumonia and upper and lower respiratory tract, skin and soft tissue, hospital-acquired lung, bone and joint infections; Staphyloccus; Enterococcus; Moraxella; Hemophilus; antibiotic resistance ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-09-02 — — US disclosed
US-20030013663-A1 6-O-CARBAMOYL KETOLIDE ANTIBACTERIALS ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-01-16 — — US disclosed
US-6472372-B1 6-O-Carbamoyl ketolide antibacterials ORTHO-MCNEIL PHARMACEUTICALS, INC. 2002-10-29 — — US disclosed
US-20020115620-A1 6-0-carbamoyl ketolide antibacterials ORTHO-MCNEIL PHARMACEUTICAL, INC. 2002-08-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030013663-A1 6-O-CARBAMOYL KETOLIDE ANTIBACTERIALS Q6ZSR9, KDM4E, HK1 RAB9A 485/4885CLK4 3779/4885DYRK1A 3256/4885
US-20070232610-A1 Novel compounds that are ERK inhibitors MAPK1, MAPK4, MAPKAPK2 RAB9A 319/4885CLK4 635/4885DYRK1A 1069/4885
US-20090306038-A1 2-Aminopyrimidine derivatives as modulators of the histamine H4 receptor activity HRH4, HRH2, HRH3 RAB9A 3144/4885CLK4 4558/4885DYRK1A 3466/4885
US-20020115620-A1 6-0-carbamoyl ketolide antibacterials Q6ZSR9, HK1, KDM4E RAB9A 442/4885CLK4 3703/4885DYRK1A 3368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.